Literature DB >> 11356910

Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block.

G A Mealing1, T H Lanthorn, D L Small, R J Murray, K C Mattes, T M Comas, P Morley.   

Abstract

Differences in the degree of trapping of initial block by N-methyl-D-aspartate (NMDA) receptor antagonists may affect their safety and, hence, suitability for clinical trials. In this comparative study, 23 compounds structurally related to the low-affinity, use-dependent NMDA receptor antagonist (S)-alpha-phenyl-2-pyridineethanamine dihydrochloride (AR-R15896AR) were examined to determine the degree of trapping block they exhibit. Compounds were tested at concentrations that produced a comparable initial 80% block of NMDA-mediated whole-cell current in rat cortical cultures. A wide range of values of trapping block was found, indicating that trapping is not an all-or-none event. Fifteen of the compounds trapped significantly more than the 54 +/- 3% of initial block trapped by AR-R15896AR. The off-rates of these compounds were slower than that of AR-R15896AR. Only 2 of the 23 compounds trapped significantly less than AR-R15896AR. AR-R15808, the piperidine analog of AR-R15896AR, appeared to trap only 8 +/- 3% of its initial block, although its fast off-rate confounded accurate quantification of trapping. AR-R26952, which, like AR-R15896AR, contains a pyridine in place of a phenyl group, trapped 40 +/- 5% of its initial block and exhibited kinetics comparable with AR-R15896AR. Structure-activity analysis suggested that the presence of two basic nitrogen atoms and decreased hydrophobicity led to decreased trapping. There was no correlation between trapping and lipophilicity as would be expected if closed-channel egress was due to escape through the lipid bilayer. However, there was a positive correlation between off-rate and degree of trapping. Models that can account for partial trapping are presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356910

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 2.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

Review 3.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

4.  Memantine binding to a superficial site on NMDA receptors contributes to partial trapping.

Authors:  Shawn E Kotermanski; Jesse T Wood; Jon W Johnson
Journal:  J Physiol       Date:  2009-08-17       Impact factor: 5.182

5.  Potentiation and Block of ASIC1a by Memantine.

Authors:  Vasiliy Y Shteinikov; Tatiana B Tikhonova; Vyacheslav S Korkosh; Denis B Tikhonov
Journal:  Cell Mol Neurobiol       Date:  2017-10-20       Impact factor: 5.046

6.  Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.

Authors:  G Sanacora; M A Smith; S Pathak; H-L Su; P H Boeijinga; D J McCarthy; M C Quirk
Journal:  Mol Psychiatry       Date:  2013-10-15       Impact factor: 15.992

7.  REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.

Authors:  Francesco Bifari; Marco Pappagallo; Michael Bleavins; Sergio Traversa; Franco Folli; Paolo L Manfredi
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.810

8.  Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.

Authors:  Ezio Bettini; Stephen M Stahl; Sara De Martin; Andrea Mattarei; Jacopo Sgrignani; Corrado Carignani; Selena Nola; Patrizia Locatelli; Marco Pappagallo; Charles E Inturrisi; Francesco Bifari; Andrea Cavalli; Andrea Alimonti; Luca Pani; Maurizio Fava; Sergio Traversa; Franco Folli; Paolo L Manfredi
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.